Concepedia

Shinji Atagi

SA

Statistics

Publications

112

Citations

7.5K

H-Index

44

Active since

1992

Affiliations

NHO Kinki Chuo Chest Medical Center(Current)

Kindai University

Osaka Prefectural Medical Center

National Hospital Organization Kyushu Cancer Center

National Cancer Center Hospital East

Shinji Atagi is an author at NHO Kinki Chuo Chest Medical Center specializing in medicine, oncology, and non-small cell lung cancer therapy.

ORCID

Publications per year

1992–2024

112

Publications

112

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology · 2014 · 749 citations

, , +14

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

, , +12

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

, , +8

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology · 2015 · 410 citations

, , +15

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Nobuyuki Katakami, Shinji Atagi, Kōichi Goto et al. · Journal of Clinical Oncology · 2013 · 324 citations · Full text

, , +15

1–5 of 112